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Abstract
Background: Human chromosomal region 8q24 contains several genes which could be functionally related to
cancer, including the proto-oncogene c-MYC. However, the abundance of associations around 128 Mb on
chromosome 8 could mask the appearance of a weaker, but important, association elsewhere on 8q24.
Methods: In this study, we completed a meta-analysis of results from nine genome-wide association studies for
seven types of solid-tumor cancers (breast, prostate, pancreatic, lung, ovarian, colon, and glioma) to identify
additional associations that were not apparent in any individual study.
Results: Fifteen SNPs in the 8q24 region had meta-analysis p-values < 1E-04. In particular, the region consisting of
120,576,000-120,627,000 bp contained 7 SNPs with p-values < 1.0E-4, including rs6993464 (p = 1.25E-07). This
association lies in the region between two genes, NOV and ENPP2, which have been shown to play a role in tumor
development and motility. An additional region consisting of 5 markers from 128,478,000 bp - 128,524,000 (around
gene POU5F1B) had p-values < 1E-04, including rs6983267, which had the smallest p-value (p = 6.34E-08). This
result replicates previous reports of association between rs6983267 and prostate and colon cancer.
Conclusions: Further research in this area is warranted as these results demonstrate that the chromosomal
region 8q24 may contain a locus that influences general cancer susceptibility between 120,576 and 120,630 kb.
Background
Human chromosomal region 8q24 has been associated
with many types of solid-tumor cancer, including cancers
of the breast [1-5], prostate [6-10], bladder [11], colon
[12-17], lung [18,19], ovaries [20], pancreas [21], and brain
[22,23] (Additional file 1). The majority of these associa-
tions lie at approximately 128 Mb on chromosome 8, with
one prominently associated SNP, rs6983267, shown to
interact with the proto-oncogene c-MYC (128.82 Mb)
[1,24]. Several studies suggest the possibility that some loci
in 8q24 influence more than one type of cancer per locus:
breast and pancreatic cancer [2]; prostate and colorectal
cancer [25]; prostate, colorectal, and ovarian cancer [20].
These studies suggest that this region may contain loci
that affect general cancer susceptibility, which interact
with other loci (in or outside of 8q24) and/or environmen-
tal factors to determine cancer type.
Therefore, to fully understand the role of 8q24 in can-
cer development, it is important to determine any addi-
tional associations that lie within this region. For
example, the region 8q24 contains several other genes
which could be functionally related to cancer develop-
ment, including NOV, which encodes a regulatory pro-
tein from the CCN family that has been associated with
cancer development [26]. Therefore, we used data from
nine genome-wide association studies (GWAS) for seven
cancers to conduct a meta-analysis for general cancer
risk loci in the entire region of 8q24.
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Methods
Nine Genome-Wide Association Studies for Cancer
The meta-analysis consisted of solid-tumor cancer GWAS
with data available via dbGaP or available to us through
collaborations, including studies of lung [27], prostate
[28], breast [29,30], and pancreatic [31] cancers from the
Cancer Genetic Markers of Susceptibility (CGEMS) pro-
ject, accessed from dbGaP; an additional lung cancer study
[32]; the Cancer Family Registry (CFR) colon cancer study
[33], a study of glioma [34], and two ovarian cancer studies
from the United Kingdom [35] and the United States [36].
Table 1 presents a summary of the nine studies. The
reader is referred to the primary papers for more extensive
study details regarding recruitment, matching of controls
and analysis methods.
The CGEMS lung cancer GWAS [27] consisted of 1629
subjects from the Prostate, Lung, Colorectal, and Ovarian
(PLCO) cancer study who provided consent for general
cancer research. The study included adenocarcinoma,
squamous cell carcinoma, small-cell lung cancer, and
other histological types. The second lung cancer GWAS
included 377 lung cancer cases and 377 matched con-
trols, all of whom were never smokers (i.e., had smoked
fewer than 100 cigarettes in their lifetime) [32]. Eighty-
one percent of the cases had non-small-cell lung cancer
(NSCLC); 68% had adenocarcinoma, a type of NSCLC.
The CGEMS prostate cancer GWAS [28] included 1151
cases and 1101 male controls from the screening arm of
the PLCO study. The cases included individuals with
aggressive and nonaggressive cancer. The CGEMS breast
cancer GWAS [29,30] consisted of 1145 cases and 1142
matched controls, all of whom were postmenopausal
women of European ancestry from the Nurses’ Health
Study. The fourth CGEMS GWAS included was the pan-
creatic cancer GWAS [31], which included 7174 subjects
drawn from cohort and case-control studies. All cases
had primary adenocarcinoma of the exocrine pancreas.
The CFR colon cancer GWAS [33] consisted of 2190
individuals. The cases had invasive colorectal cancer and
no identified germline mutations in mismatch repair pro-
teins. The cases were self-identified as non-Hispanic white
and had microsatellite stable or low microsatellite instabil-
ity colorectal cancer (CRC) and/or MMR protein immuno-
histochemistry positive determined using standard
methods [37]. The glioma GWAS [34] included 176 cases
and 174 controls from the Mayo Clinic. The cases were
adults with high-grade glioblastoma or anaplastic astrocy-
toma. Finally, the UK ovarian cancer GWAS [35,38]
involved 1817 cases and 2353 controls, while the US ovar-
ian GWAS [36] included 1,815 cases and 1,900 controls
from four epithelial ovarian cancer (EOC) case-control
studies.
Table 1 Summary of the nine GWAS included in the meta-analysis for 8q24
Cancer Ref Study Study
size
Cases Controls Cancer subtypes Study Notes
Ovarian [35,38] UK 4170 1817 2353 Majority of controls from UK 1958 birth
cohort
Ovarian [36] US 3715 1815 1900 epithelial ovarian cancer Four incident case-control studies: Mayo
Clinic Ovarian Cancer Study, Duke
University’s
North Carolina Ovarian Cancer Study,
University of Toronto Familial Ovarian Tumor
Study,
H. Lee Moffitt Cancer Center and Research
Institute’s Tampa Bay Ovarian Cancer Study
Glioma [34] Mayo Clinic 350 176 174 high-grade glioblastoma, anaplastic
astrocytoma
Lung [32] Mayo Clinic 754 377 377 adenocarcinoma, other Cases and controls were never smokers (i.e.,
had smoked fewer than
100 cigarettes in their lifetime)
Lung [27] CGEMS/PLCO 1629 ~800 ~800 adenocarcinoma, squamous cell
carcinoma, small-cell lung cancer,
other
Cases and controls consisted of both
smokers & non-smokers
Prostate [28] CGEMS/PLCO 2252 1151 1101 aggressive, non-aggressive
Breast [29,30] CGEMS/
Nurses’ Health
Study
2287 1145 1142 Postmenopausal women with matching
based on use of hormone replacement
therapy
Pancreatic [31] CGEMS/
PanScan
7174 3532 3642 primary adenocarcinoma of the
exocrine pancreas
Consisted of 12 cohort and 8 case-control
studies
Colon [33] Colon Family
Registry (CFR)
2190 ~1000 ~1000 invasive, microsatellite stable or low
microsatellite instability colorectal
cancer
Cases had no germline mismatch repair
mutations
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Meta-analysis
The meta-analysis included 6686 SNPs across the 8q24
region, from rs6469653 (117.7 Mb) to rs7822726 (146.2
Mb), which were genotyped and/or imputed in at least
five studies. P-values from an additive genetic model for
the nine cancer GWAS were combined using Fisher’s
method [39] and Stouffer’s (Lipták) method [40], which
each use different transformations for combining m
independent p-values (pi, i = 1, ..., m) into a test statis-
tic. In particular, the test statistic for Fisher’s method is
F = −2
m∑
i=1
log
(
pi
)
, while the test statistic for Stouffer’s
method is S =
m∑
i=1
Zi
/√
m , with Zi = F
-1(pi), where F
-1
(·) is the inverse standard normal cumulative distribu-
tion function. Loughin [41] recommended that Fisher’s
method be used to emphasize small p-values, while
Stouffer’s method is preferable for putting equal weight
on p-values at both extremes. Therefore, for the meta-
analysis both Fisher’s and Stouffer’s methods were used
to assess robustness of the findings.
Many meta-analyses weight results by the sample size
of the studies included [42]. This practice is useful for
meta-analyses based on averaging effect sizes, as larger
studies are expected to have more accurate estimates of
effect sizes [43]. However, meta-analyses based on p-
values, such as this one, already incorporate sample size,
as smaller studies contain less evidence and cannot have
extremely small p-values. Simulations demonstrate that
further weighting the analysis by sample size can bias the
results toward the largest study and decrease power to
detect effects shared only among the smaller studies
(Additional file 2). For this reason, equal weight was
given to each cancer type in the meta-analysis. Each of
the two lung cancer studies and each of the two ovarian
studies received a weight of one-half. The Fisher’s meta-
analysis was weighted according to the method of Hou
[44].
In addition to the meta-analysis based on combination
of p-values, analysis was also completed based on the
number of individual studies in which the SNP had an
individual association p-value less than 0.10, with the p-
value based on a binomial distribution conditioned on the
number of studies in which each SNP was genotyped.
Linkage disequilibrium (LD) plots and statistics for Eur-
opeans (CEU) were derived from HapMap release 27
(http://hapmap.ncbi.nlm.nih.gov/downloads/ld_data/lat-
est/; [45]). LocusZoom (http://csg.sph.umich.edu/locus-
zoom/; [46]) was used to plot association results.
Results
Fifteen SNPs had meta-analysis p-values below 1E-04, as
shown in Table 2. The region chr8: 120,576,000-
120,627,000 bp contains 7 SNPs with meta-analysis p-
values < 1.0E-5 (Figures 1A and 1B), including
rs6993464 (Fisher’s p = 1.25E-07), which had the sec-
ond-most significant p-value of the 6686 SNPs exam-
ined within 8q24. This p-value is significant after
Bonferroni correction (p = 0.0025). In addition, two of
the 7 SNPs had Stouffer’s p-values < 1E-04, including
rs6993464 (Stouffer’s p = 6.92E-07). The agreement
between the Fisher and Stouffer results demonstrates
robustness of the result to the choice of transformation
used in combining the p-values.
As shown in Table 2, rs6993464 is also the site of a
weaker association peak in the CGEMS pancreatic cancer
GWAS (p = 6.39E-05). However, the SNP rs6993464
retains a p-value of 7.94E-05 when the pancreatic cancer
study is omitted from the analysis, suggesting that the
association at rs6993464 is not solely driven by the pan-
creatic cancer study. Along with pancreatic cancer, the
CGEMS lung and breast cancer datasets contribute the
most to the significance of the meta-analysis p-values in
this region, with study-specific p-values at these seven
SNPs ranging from 0.008 to 5.45E-04. Unlike the
CGEMS lung cancer GWAS, the never-smokers lung
cancer GWAS did not contribute to the association sig-
nal at rs6993464 or nearby SNPs. This could be due to
sample size, as the never-smokers dataset included fewer
individuals (754 vs. 1629), or to gene-environment inter-
action, as the CGEMS lung cancer study included smo-
kers, while the non-CGEMS lung cancer study did not.
An additional region consisting of 5 markers from
128,478,000 bp - 128,524,000 (around gene POU5F1B)
had Fisher’s p-values < 1E-04, including rs6983267,
which had the smallest p-value in the meta-analysis (p =
6.34E-08) (Figure 1C). SNP rs10808555, and another
SNP just outside the region (rs17464492; 128,412,048
bp), had p-values < 0.10 in 6 out of the 9 individual
GWAS (binomial p = 6.4E-05). This result replicates
previous reports of association between rs6983267 and
prostate [20] and colon cancer [14-16,20], but provides
conflicting evidence with respect to reports of associa-
tion with ovarian cancer [20], as the UK ovarian study
provided nominal support for association with
rs6983267 (p = 0.022) while the US ovarian GWAS did
not (p = 0.81).
Finally, two additional SNPs were found to be asso-
ciated with cancer in the meta-analysis. An association
at rs7837688 (128,608,542 bp; p = 7.80E-05) was primar-
ily due to association with prostate cancer (individual
study p = 1.02E-06). An association at rs6470494
(128,157,086 bp; p = 3.73E-05) showed some evidence
of being a general cancer risk locus, as its significance
was contributed by multiple data sets (colon, breast, and
UK ovarian). However, this association was not as well
supported by associations at neighboring SNPs.
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Table 2 Top meta-analysis results.
Individual Study P-value Meta-analysis P-value
SNP bp Breast1 Prostate1 Pancreatic1 Lung1 Lung2 Ovarian3 Ovarian4 Glioma5 Colon6 Fisher Stouffer Binomial
rs1695718 118458790 0.14 0.40 0.82 0.19 - 0.95 0.03 5.45E-05 0.23 7.94E-04 8.92E-03 0.19
rs7846200 120576453 1.08E-03 0.18 7.52E-04 6.20E-03 - 0.87 0.61 0.40 0.39 1.51E-05 1.01E-04 0.04
rs7000665 120576919 1.73E-03 0.22 1.12E-04 8.44E-03 - 0.90 0.54 0.62 0.45 1.11E-05 2.39E-04 0.04
rs10505364 120578285 1.53E-03 0.27 2.97E-04 3.16E-03 0.75 0.82 0.46 0.37 0.39 2.94E-05 3.72E-04 0.05
rs9643136 120609324 5.45E-04 0.34 1.15E-04 5.30E-03 0.50 0.99 0.58 0.70 0.36 1.36E-05 1.78E-03 0.05
rs6993464 120614129 2.17E-03 0.17 6.39E-05 6.45E-04 - 0.81 0.22 0.21 0.24 1.25E-07 6.92E-07 0.04
rs11782176 120617858 2.16E-03 0.20 5.55E-05 5.61E-04 - 0.76 - 0.24 0.25 5.24E-07 6.86E-06 0.03
rs6991756 120626148 4.33E-03 0.24 5.01E-05 1.15E-03 1.00 0.69 0.24 0.24 0.23 3.17E-06 1.34E-04 0.05
rs3870371 122766313 4.23E-05 0.57 0.62 0.38 0.82 0.23 0.16 0.69 0.72 9.12E-03 0.12 0.61
rs920455 122769378 3.30E-05 0.65 0.64 0.41 0.68 0.16 0.18 0.85 0.76 9.26E-03 0.17 0.61
rs6470494 128157086 9.43E-04 0.36 0.16 0.96 0.57 2.88E-03 0.93 0.57 5.85E-04 3.73E-05 1.60E-03 0.05
rs17464492 128412048 0.21 0.04 0.08 0.92 0.09 6.14E-03 1.21E-02 0.72 1.18E-02 3.92E-04 4.80E-04 6.42E-05
rs10808555 128478693 6.35E-03 1.29E-02 0.81 0.05 0.05 3.87E-03 0.78 0.53 8.82E-03 4.64E-05 1.91E-04 6.42E-05
rs6983267 128482487 8.37E-03 1.05E-05 0.25 0.39 0.16 0.02 0.81 0.49 1.40E-03 6.34E-08 1.28E-06 8.33E-03
rs7837328 128492309 3.88E-03 8.68E-04 0.63 0.23 - 9.83E-03 0.84 0.62 1.41E-02 4.40E-05 3.02E-04 5.02E-03
rs7014346 128493974 6.19E-03 2.83E-03 0.69 0.18 0.23 0.02 0.98 0.49 1.02E-02 8.48E-05 6.32E-04 8.33E-03
rs12334695 128523110 0.14 4.34E-04 0.02 0.53 0.96 0.03 0.74 3.09E-02 0.47 8.46E-05 4.43E-04 8.33E-03
rs1447295 128554220 0.64 2.44E-05 0.52 0.46 0.24 0.17 0.27 0.12 0.73 1.26E-03 1.45E-02 0.61
rs4242382 128586755 0.83 2.82E-06 0.43 0.60 0.13 0.19 0.16 0.13 0.99 2.26E-04 0.06 0.61
rs4242384 128587736 0.87 2.66E-06 0.49 0.58 - 0.21 0.30 0.17 0.95 1.08E-03 0.11 0.57
rs7017300 128594450 0.73 1.80E-05 0.85 0.95 0.15 0.39 0.60 8.45E-02 0.58 2.03E-03 0.09 0.23
rs11988857 128601055 0.65 3.78E-06 0.97 0.87 - 0.16 0.37 5.68E-02 0.97 1.12E-03 0.29 0.19
rs7837688 128608542 0.88 1.02E-06 0.65 0.92 0.11 0.22 0.23 5.37E-02 0.74 7.80E-05 0.02 0.23
rs4404878 128867576 0.89 0.21 3.02E-05 0.06 0.50 0.05 0.17 0.10 0.97 3.20E-04 0.02 0.05
rs7841347 128887490 0.82 0.09 3.25E-05 0.06 0.38 0.54 0.27 0.25 0.86 7.96E-04 1.68E-02 0.05
rs16903097 129625538 0.59 0.92 0.39 0.05 - 1.98E-02 9.16E-05 0.14 0.33 1.08E-02 0.03 0.04
rs2163951 130672539 0.43 0.81 0.56 0.46 0.51 0.87 0.98 0.65 9.72E-05 0.03 0.35 0.61
rs6470863 132015998 0.55 0.32 0.87 5.38E-05 0.88 0.80 0.63 0.20 0.41 0.14 0.33 0.61
SNP markers with p ≤ .0001 (bold) for either the individual GWAS or the meta-analysis with SNP present in at least five studies, sorted based on base-pair position (bp) on chromosome 8. A dash indicates no data.
Results from 1CGEMS, 2Li et al [32], 3Song et al [35]; 4Permuth-Wey et al [36]; 5Wrensch et al [34]; 6CFR [33]
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Figure 1 Individual GWAS top results and meta-analysis results for 8q24 region. (A) -log10(p-values) from meta-analysis using Fisher’s
method of the 8q24 region; (B) -log10(p-values) from meta-analysis for the region around NOV and ENPP2. Purple diamond = rs6993464; gray =
no LD data available in HapMap Phase II. Other colors indicate level of LD with rs6993464. (C) -log10(p-values) from meta-analysis using Fisher’s
method for the region around rs6983267. Purple diamond = rs6983267; colors indicate level of LD with rs6983267.
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This meta-analysis used equal weights for each cancer
type; however, the studies included ranged in size from
350 subjects to 7174 subjects. As a sensitivity analysis,
we also conducted a meta-analysis weighting each study
by its sample size (Additional file 3). This analysis did
not change the conclusions for rs6983267 (sample-
weighted Fisher’s p = 9.01E-05) or rs6993464 (p =
3.75E-07). However, the sample size-weighted analysis
did result in a third region, 128,853 - 128,888 kb, show-
ing p-values < 1E-04. The significance of this region was
primarily due to the largest study, the pancreatic cancer
data set. This region overlaps the gene PVT1, which has
previously been implicated in breast and ovarian cancer
[47]; however, in our analysis this region had nominal
evidence of association with ovarian cancer (p = 0.017
at rs10956390 in the US ovarian data set) and no evi-
dence of association with breast cancer.
Discussion
Previous studies of the 8q24 region have identified asso-
ciations between multiple types of cancer and markers
around 128 Mb; in particular, rs6983267 has been asso-
ciated with colon [20], prostate [14-16,20], and ovarian
cancer [20]. This meta-analysis reproduces the associa-
tion between rs6983267 and cancer, with four additional
SNPs in the region 128,158,000 - 128,524,000 bp having
Fisher’s meta-analysis p-values < 1E-04. SNP marker
rs6983267 has been shown to exhibit long-range physical
interaction with the proto-oncogene c-MYC (about 335
kb downstream) in colorectal, prostate, and breast cancer
[1,24], providing a potential mechanism for the source of
this association.
In addition to the association at rs6983267, we identified
a second SNP, rs6993464, associated with cancer risk. This
SNP is not in LD with rs6983267 or other loci that have
previously been reported to be associated with various
cancers (Additional file 1). It is possible that the associa-
tion at rs6993464 is due to several distinct variants, each
of which influences a different type of cancer, rather than
a single locus that influences cancer development for mul-
tiple cancers. This result would also be of interest, as it
would imply the existence of previously unreported can-
cer-specific variants in 8q24. As shown in Figure 1B,
rs6993464 and six other SNPs with meta-analysis p-values
< 1E-04 lie between the genes NOV (nephroblastoma
overexpressed gene) and ENPP2 (ectonucleotide pyropho-
sphatase/phosphodiesterase 2). NOV encodes the regula-
tory protein CCN3, which plays an important role in
cancer development [26]. ENPP2 encodes a phospholipase
which stimulates tumor cell motility and catalyzes the pro-
duction of lysophosphatidic acid, which stimulates cell
proliferation [48]. ENPP2 has also been reported to have
angiogenic properties and its expression is up-regulated in
several kinds of carcinomas [49]. Furthermore, MetaCore
(GeneGo Inc., St. Joseph, MI) regulatory network analysis
[50] indicated that both NOV and ENPP2 are indirectly
regulated by the 8q24 proto-oncogene c-MYC (Figure 2),
via p53 (for NOV) [51,52] and ESR2 (for ENPP2) [53,54],
indicating their potential involvement in a pathway for
cancer susceptibility. Therefore, it is functionally plausible
that this region contains a locus for general cancer sus-
ceptibility via cis regulation of NOV and/or ENPP2.
It is also possible that this region harbors an enhancer
locus for a more distant oncogene. Several of the signifi-
cant SNPs in this region are found in the SCAN database
[55] as expression quantitative trait loci (eQTLs) for genes
throughout the genome which are associated with various
types of cancer. In particular, rs6993464 has been shown
to be an eQTL for POLR2F, a gene on chromosome 22
which is up-regulated in colorectal cancer [56], while
rs7000665 regulates expression of BRAF, a gene which
plays an important role in tumorigenesis in thyroid cancer
[57] and melanoma [58], as well as in survival in colon
cancer [59]. Finally, rs7846200 has been reported to be an
eQTL for multiple genes associated with cancer, including
PTBP1, which affects the invasive capacity of cancer cell
lines in a cell type-dependent manner [60], and HNRNPK,
which interacts with the oncogene p53 and contributes to
pancreatic cancer [61] and has been associated with pros-
tate cancer [62].
An additional locus, rs11987056, which is in perfect LD
with rs6993464 (r2 = 1), is highly conserved and only 170
bp downstream from the putative transcription factor
binding sites V$S8_01 and V$NKX25_02 using the Trans-
fac Matrix Database (v.7.0) [63]. This SNP is associated
with expression of the proto-oncogene SRC, which is
involved in the regulation of cell growth [64]. The SNP
rs11987056 was not included in this analysis as it was gen-
otyped in only two of the individual studies examined.
Nonetheless, it is a strong functional candidate for the
source of the association between rs6993464 and cancer
development. Hence, there are several plausible mechan-
isms by which a locus in chromosome 8: 120,576,000 -
120,626,000 could affect general cancer susceptibility,
explaining our meta-analysis findings.
Because Fisher’s and Stouffer’s tests are union-intersec-
tion tests [65], the meta-analysis peak at rs6993464 is not
sufficient to conclude that the SNP is associated with
multiple cancer types, only that it is associated with at
least one type of cancer. However, the fact that
rs6993464 retains a p-value of 7.94E-05 when pancreatic
cancer, the study with the strongest association, is
omitted from the analysis suggests that this locus is asso-
ciated with more than one type of cancer in our study.
Loci that affect general cancer susceptibility may act in a
context-dependent manner; based on genetic background
at other loci, tissue type, and other environmental factors,
a particular variant could predispose for some types of
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cancers, while protecting against others. P-value based
meta-analyses, in combination with two-sided tests of
association such as those used the studies included here,
are powered to detect opposite-directional associations.
Among the three data sets which contributed the most
significance at rs6993464, the T allele was associated
with cancer risk in breast and pancreatic cancer, but with
a protective effect in the CGEMS lung cancer data set. In
the future, functional studies to establish the causal var-
iant(s) that result in the association peak at rs6993464
may determine whether the opposite-directional associa-
tion is due to context-dependent effects or to LD with
distinct, tumor-specific modifiers.
A limitation of the current study is that the CGEMS
lung and prostate cancer studies both drew samples
from the PLCO Trial, and therefore the sets of controls
overlapped. The pancreatic controls also included some
individuals from PLCO (n ≤ 423), which may have
overlapped with the lung and prostate cancer studies,
and some controls from the Nurses’ Health Study (n ≤
166), which may overlapped with the breast cancer con-
trols. Overlapping sets of controls could lead to inflation
of -log10 p-values when the results are combined. How-
ever, when the prostate and pancreatic studies were
omitted from the meta-analysis, thus removing any
overlap in controls, rs6993464 retained a p-value of
6.89E-05. Similarly, marker rs6983267 had a p-value of
6.57E-08 when overlapping controls were removed by
omitting the lung and pancreatic cancer data sets. This
suggests that the overlapping sets of controls do not
affect the overall conclusion of possible cancer risk loci
around rs6983267 and rs6993464.
In the future, it would be beneficial to extend this
analysis to include bladder cancer, another cancer type
which has been associated with 8q24 [11]. It would also
be advantageous to examine rs6993464 in the context of
Figure 2 Regulatory relationship between NOV, ENPP2, and c-MYC, reconstructed using MetaCore.
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cancer-specific GWAS, conditioning on other loci which
have been reported to be associated with these cancer
types. This could clarify the role of rs6993464 among
other loci that influence cancer susceptibility. This study
demonstrates the power of meta-analysis for secondary
phenotypes in identifying loci that may affect general
cancer susceptibility. In the future, it would be valuable
to conduct meta-analyses of subsets of solid-tumor can-
cer types with additional common features, such as
breast, pancreatic, and colorectal cancer, which share
the feature of frequent somatic amplification of 8q24
[20,25].
Conclusions
In summary, this meta-analysis of nine existing GWAS
for solid-cancers indicates a possible cancer risk locus
on 8q24 (120,576,000-120,626,000 bp) between NOV
and ENPP2, both of which are involved in carcinogen-
esis and have a regulatory relationship with the proto-
oncogene c-MYC. We were also able to replicate pre-
vious findings for rs6983267, which has been implicated
in risk for multiple cancers and known to have long-
range physical interaction with the proto-oncogene c-
MYC. Future research in this area is warranted to deter-
mine the mechanism by which this region may influence
general cancer risk, as well as its genetic and environ-
mental interactions with other known risk factors.
Additional material
Additional file 1: Location of SNPs previously reported to be
associated with cancer. The novel association, rs6993464, is indicated
by the purple star. P-value plotted for previously reported associations is
minimum from previous reports. Dark blue color indicates r2 < 0.2. Shape
of points indicates type of cancer with which the locus has been
associated; there is no symbol for ovarian cancer because rs6983267,
rs10808556, and rs10505477 have been associated with multiple cancer
types (downward-pointing triangles). Lung cancer has been associated
with rs6983267 (multiple cancer associations, downward-pointing
triangle) and deletion D8S272 (137.8 Mb, not shown).
Additional file 2: Power of weighted and unweighted meta-
analyses. Three studies of size 350, 350, and 5000 were simulated
according to a logistic model with log(OR) = Beta*x, where x is the
genotype (-1, 0, 1). Power at alpha = 0.05 (over 1000 simulations) is
shown for Fisher’s meta-analyses with weights proportional to study size
and with equal weights.
Additional file 3: Effect of sample size weighting on meta-analysis
results. SNP markers with p ≤ .0001 (bold) for the Fisher or Stouffer
meta-analysis, weighted by cancer type or sample size. SNPs are sorted
based on base-pair position (bp) on chromosome.
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